One-year outcomes with two suture-mediated closure devices to achieve access-site haemostasis following transfemoral transcatheter aortic valve implantation

Julinda Mehilli; David Jochheim; Mohamed Abdel‐Wahab; Konstantinos D. Rizas; Hans Theiß; Nina Spenkuch; Magda Zadrozny; Moritz Baquet; Mohamed El‐Mawardy; Takao Sato; Philipp Lange; Christian Kuppatt; Martin Greif; Jörg Hausleiter; Axel Bauer; Florian Schwarz; Maximilian Pichlmaier; Christian Hagl; Gert Richardt; Steffen Maßberg

doi:10.4244/eijv12i10a213

Why the study?

Does ProGlide SMCD reduce vascular and bleeding complications compared to Prostar SMCD in patients undergoing transfemoral TAVI?

Key Points

To compare one-year vascular, bleeding, and mortality outcomes associated with ProGlide versus Prostar suture-mediated closure devices after transfemoral transcatheter aortic valve implantation.
Evaluated patients undergoing transfemoral transcatheter aortic valve implantation (TAVI) who received either ProGlide or Prostar suture-mediated closure devices (SMCD) for access-site haemostasis.
Assessed post-procedural access-site vascular and bleeding complications alongside one-year all-cause mortality rates.
Use of the ProGlide SMCD was associated with a reduced risk of vascular and bleeding complications after TAVI compared to the Prostar SMCD.
Major vascular complications independently predicted long-term mortality, whereas the specific use of ProGlide did not independently predict long-term mortality.

Structured PICO

Does ProGlide SMCD reduce vascular and bleeding complications compared to Prostar SMCD in patients undergoing transfemoral TAVI?

P

Population

Patients undergoing transfemoral transcatheter aortic valve implantation (TAVI)

I

Intervention

ProGlide suture-mediated closure device (SMCD)

C

Comparator

Prostar suture-mediated closure device (SMCD)

O

Outcome

Vascular and bleeding complicationssafety

Implication

The use of ProGlide SMCD for access-site hemostasis in transfemoral TAVI is associated with fewer vascular and bleeding complications than Prostar SMCD.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mehilli et al. (2016) studied this question.

synapsesocial.com/papers/69db57230d8d6ef495a3d522 https://doi.org/10.4244/eijv12i10a213

View at Publisher

Ask AI

Bookmark

Share

One-year outcomes with two suture-mediated closure devices to achieve access-site haemostasis following transfemoral transcatheter aortic valve implantation

Key Points

Structured PICO

Implication

Abstract

Discussion

Cite This Study

One-year outcomes with two suture-mediated closure devices to achieve access-site haemostasis following transfemoral transcatheter aortic valve implantation

Key Points

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading